CRISCuris

About Curis
Curis (NASDAQ:CRIS) focuses on innovating and developing new treatments in the fight against cancer. With a passion for leveraging the latest in molecular and cancer biology to unlock new therapeutic pathways, Curis is dedicated to the discovery and development of groundbreaking drug candidates. The company's projects span various stages of clinical trials, aiming to address some of the most challenging oncological targets. Central to their mission is the objective to provide novel, effective therapies to improve the lives of patients struggling with cancer. By pushing the boundaries of current treatment paradigms, Curis endeavors to make significant contributions to oncology and patient care.
What is CRIS known for?
Snapshot
Public US
Ownership
2000
Year founded
49
Employees
Lexington, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Produtos e/ou serviços de Curis
- CA-170, a first-in-class oral small molecule targeting PDL1 and VISTA for advanced solid tumors and lymphomas.
- CA-4948, an IRAK4 inhibitor aimed at treating patients with non-Hodgkin lymphoma.
- Fimepinostat, a dual inhibitor of PI3K and HDAC for the treatment of patients with lymphomas.
- CA-327, a first-in-class oral small molecule targeting PDL1 and TIM3 for advanced solid tumors and lymphomas.
- Collaboration with Aurigene in the discovery and development of small molecule therapeutics in oncology.
equipe executiva do Curis
- Mr. James E. DentzerPresident, CEO, Secretary, Treasurer & Director
- Ms. Diantha Duvall CPA, M.B.A.CFO and Principal Financial & Accounting Officer
- Dr. Jonathan B. Zung Ph.D.Chief Development Officer
- Mr. Mark W. NoelVice President of Technology Management & Intellectual Property
- Dr. Robert E. Martell M.D., Ph.D.Chief Scientific Officer
- Ms. Nancy SoohooVP & General Counsel
- Ms. Rachel BlasbalgSenior Director of Human Resources
- Dr. Ahmed M. Hamdy M.D.Chief Medical Officer